PLAU and non-small cell lung carcinoma: These results indicate that Loureirin A and Loureirin B effectively inhibit the activity of MMP-2 and MMP-9 and suppress the expression of u-PAR, u-PA, and MT1-MMP, thereby attenuating the invasive potential of human NSCLC cells.